FindTrial
Sign In

BMS-986177

DRUG13 trials

Sponsors

Bristol-Myers Squibb

Conditions

Acute Ischemic StrokeAntithromboticESRD (End-Stage Renal Disease)Factor XIHealthy VolunteersRenal ImpairmentThrombosisTransient Ischemic Attack (TIA)

Phase 1

Safety and Tolerability Study of BMS-986177 in Healthy Subjects
CompletedNCT02608970
Bristol-Myers SquibbThrombosis
Start: 2015-12-31End: 2017-07-23Updated: 2017-07-31
A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects
CompletedNCT02807909
Bristol-Myers SquibbThrombosis
Start: 2016-07-31End: 2016-08-31Updated: 2016-09-12
A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
CompletedNCT02902679
Bristol-Myers SquibbESRD (End-Stage Renal Disease), Factor XI, Renal Impairment +1
Start: 2016-11-30End: 2017-06-30Updated: 2017-07-27
A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects
CompletedNCT02959060
Bristol-Myers SquibbThrombosis
Start: 2016-11-30End: 2016-12-31Updated: 2017-01-06
Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
CompletedNCT02982707
Bristol-Myers SquibbThrombosis
Start: 2018-03-01End: 2018-09-28Updated: 2018-11-14
A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis
CompletedNCT03000673
Bristol-Myers SquibbAntithrombotic
Start: 2017-05-23End: 2017-10-23Updated: 2020-12-29
Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
CompletedNCT03196206
Bristol-Myers SquibbThrombosis
Start: 2017-07-13End: 2018-03-04Updated: 2022-06-10
To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants
CompletedNCT03224260
Bristol-Myers SquibbThrombosis
Start: 2017-06-28End: 2017-11-07Updated: 2018-06-01
An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants
CompletedNCT03341390
Bristol-Myers SquibbHealthy Volunteers
Start: 2017-10-18End: 2017-11-16Updated: 2018-01-19
Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants
CompletedNCT03362437
Bristol-Myers SquibbThrombosis
Start: 2017-11-15End: 2017-12-28Updated: 2018-03-14
A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects
CompletedNCT03698513
Bristol-Myers SquibbHealthy Volunteers
Start: 2018-10-04End: 2019-02-19Updated: 2021-09-29
Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants
CompletedNCT03939702
Bristol-Myers SquibbThrombosis
Start: 2019-05-02End: 2019-07-11Updated: 2019-10-04

Phase 2

A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
CompletedNCT03766581
Bristol-Myers SquibbAcute Ischemic Stroke, Transient Ischemic Attack (TIA)
Start: 2019-01-27End: 2022-03-31Updated: 2023-06-12

Related Papers

Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants.
2024-07-181 citations
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
2024-01-0153 citations
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor.
2022-12-2312 citations
Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment.
2022-07-3015 citations
Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor.
2022-05-3115 citations
Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
Clinical Pharmacokinetics2022-03-0932 citations